Trevi Therapeutics, Inc. (TRVI) — Stock Valuation & Research

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products…

TRVI key statistics

Price$13.85
Market cap$1.97B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range9.82-20.22
Beta0.98

Explore TRVI's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.